David P. Southwell

Mr. Southwell has been President and CEO since August 2014, and led Inotek through its IPO and secondary financing. He was previously CFO of Human Genome Sciences and Sepracor, Inc. His experience includes boards of directors (Human Genome Sciences (HGSI), PTC Therapeutics (PTCT), THL Credit (TCRD), and Biosphere Medical (BSMD), and the Board of Overseers at the Tuck School of business at Dartmouth College. He has completed over $3 Billion of financings; and mounted a going-private bid for Sepracor in 2008.